Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
Cayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.
Click Us!
KDMF
CA,
Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.
Chirogate is a professional Prostaglandin manufacturer.
NDC
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
ASMF, CN
TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Jai Radhe Sales is your partner for all your sourcing needs.
Century has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
Capital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Italy
Brand Name : LUMIGAN
Dosage Form : Eye Drops Solution For Ophthalmic
Dosage Strength : 0.1 mg/ml
Packaging : 3 ML 0.1 MG/ML - OPHTHALMIC USE SOLUTION
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : LUMIGAN
Dosage Form : Eye Drops Solution For Ophthalmic
Dosage Strength : 0.3 mg/ml
Packaging : 30 UNITS 0.4 ML 0.3 MG/ML - OPHTHALMIC USE SOLUTION
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : GANFORT
Dosage Form : Eye Drops
Dosage Strength : 0.3 mg/ml + 5 mg/ml
Packaging : 3 ML 0.3 MG/ML + 5 MG/ML - OPHTHALMIC USE SOLUTION
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Lumigan
Dosage Form : Gtt Opht
Dosage Strength : 0.1mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Lumigan
Dosage Form : Gtt Opht
Dosage Strength : 0.1mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Lumigan Unit Dose
Dosage Form : Gtt Opht
Dosage Strength : 0.3mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Lumigan Unit Dose
Dosage Form : Gtt Opht
Dosage Strength : 0.3mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Ganfort
Dosage Form : Gtt Opht
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Ganfort
Dosage Form : Gtt Opht
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Ganfort Unit Dose
Dosage Form : Gtt Opht
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : LUMIGAN RC
Dosage Form : SOLUTION
Dosage Strength : 0.01%/W/V
Packaging :
Approval Date :
Application Number : 2324997
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : LATISSE
Dosage Form : SOLUTION
Dosage Strength : 0.03%/W/V
Packaging :
Approval Date :
Application Number : 2350939
Regulatory Info : Prescription
Registration Country : Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Lumigan PF
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Lumigan PF
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Lumigan
Dosage Form : eye drops
Dosage Strength : 0.03%
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Lumigan PF
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Lumigan
Dosage Form : eye drops
Dosage Strength : 0.03%
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Lumigan
Dosage Form : eye drops
Dosage Strength : 0.03%
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Parenteral
Solubilizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory FDF Prices
RX/OTC/DISCN :
Dosage Form : Eye Drops Solution For Ophthalmi...
Dosage Strength : 0.1 mg/ml
Price Per Pack (Euro) : 15.3
Published in :
Country : Italy
RX/OTC/DISCN :
RX/OTC/DISCN : Class A
Dosage Form : Bimatoprost 0.1Mg/Ml 3Ml Solutio...
Dosage Strength : EYE DROPS 3 ml 0. 1 mg/ml
Price Per Pack (Euro) : 19.63
Published in :
Country : Italy
RX/OTC/DISCN : Class A
RX/OTC/DISCN :
Dosage Form : Eye Drops
Dosage Strength : 0.3 mg/ml + 5 mg/ml
Price Per Pack (Euro) : 15.26
Published in :
Country : Italy
RX/OTC/DISCN :
RX/OTC/DISCN :
Dosage Form : Eye Drops Solution For Ophthalmi...
Dosage Strength : 0.3 mg/ml
Price Per Pack (Euro) : 22.4
Published in :
Country : Italy
RX/OTC/DISCN :
RX/OTC/DISCN : Class B
Dosage Form : Gtt Opht
Dosage Strength : 0.1mg/ml
Price Per Pack (Euro) : 14.66
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : Class B
Dosage Form : Gtt Opht
Dosage Strength : 0.1mg/ml
Price Per Pack (Euro) : 41.16
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : Class B
Dosage Form : Gtt Opht
Dosage Strength : 0.3mg/ml
Price Per Pack (Euro) : 17.82
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : Class B
Dosage Form : Gtt Opht
Dosage Strength : 0.3mg/ml
Price Per Pack (Euro) : 50.8
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : Class B
Dosage Form : Gtt Opht
Dosage Strength :
Price Per Pack (Euro) : 18.92
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : Class B
Dosage Form : Gtt Opht
Dosage Strength :
Price Per Pack (Euro) : 53.99
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : Ophthalmology
Currency : USD
2020 Revenue in Millions : 378
2019 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Ophthalmology
Currency : USD
2021 Revenue in Millions : 579
2020 Revenue in Millions : 378
Growth (%) : 53
Main Therapeutic Indication : Ophthalmology
Currency : USD
2022 Revenue in Millions : 514
2021 Revenue in Millions : 579
Growth (%) : -11
Main Therapeutic Indication : Ophthalmology
Currency : USD
2023 Revenue in Millions : 432
2022 Revenue in Millions : 514
Growth (%) : -16
Main Therapeutic Indication : Ophthalmology
Currency : USD
2024 Revenue in Millions : 429
2023 Revenue in Millions : 432
Growth (%) : -1
Main Therapeutic Indication : Ophthalmology
Currency : USD
2017 Revenue in Millions : 689
2016 Revenue in Millions : 688
Growth (%) : 0.1
Main Therapeutic Indication : Ophthalmology
Currency : USD
2018 Revenue in Millions : 684
2017 Revenue in Millions : 689
Growth (%) : -1%
Main Therapeutic Indication : Ophthalmology
Currency : USD
2016 Revenue in Millions : 688
2015 Revenue in Millions : 544
Growth (%) : 26
Main Therapeutic Indication : Hypotrichosis of Eyelashes
Currency : USD
2017 Revenue in Millions : 65
2016 Revenue in Millions : 86
Growth (%) : -25
Main Therapeutic Indication : Ophthalmology
Currency : USD
2019 Revenue in Millions : 630
2018 Revenue in Millions : 684
Growth (%) : -8
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
71
PharmaCompass offers a list of Bimatoprost API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bimatoprost manufacturer or Bimatoprost supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bimatoprost manufacturer or Bimatoprost supplier.
PharmaCompass also assists you with knowing the Bimatoprost API Price utilized in the formulation of products. Bimatoprost API Price is not always fixed or binding as the Bimatoprost Price is obtained through a variety of data sources. The Bimatoprost Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A bimatoprostum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of bimatoprostum, including repackagers and relabelers. The FDA regulates bimatoprostum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. bimatoprostum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of bimatoprostum manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A bimatoprostum supplier is an individual or a company that provides bimatoprostum active pharmaceutical ingredient (API) or bimatoprostum finished formulations upon request. The bimatoprostum suppliers may include bimatoprostum API manufacturers, exporters, distributors and traders.
click here to find a list of bimatoprostum suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A bimatoprostum DMF (Drug Master File) is a document detailing the whole manufacturing process of bimatoprostum active pharmaceutical ingredient (API) in detail. Different forms of bimatoprostum DMFs exist exist since differing nations have different regulations, such as bimatoprostum USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A bimatoprostum DMF submitted to regulatory agencies in the US is known as a USDMF. bimatoprostum USDMF includes data on bimatoprostum's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The bimatoprostum USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of bimatoprostum suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The bimatoprostum Drug Master File in Japan (bimatoprostum JDMF) empowers bimatoprostum API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the bimatoprostum JDMF during the approval evaluation for pharmaceutical products. At the time of bimatoprostum JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of bimatoprostum suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a bimatoprostum Drug Master File in Korea (bimatoprostum KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of bimatoprostum. The MFDS reviews the bimatoprostum KDMF as part of the drug registration process and uses the information provided in the bimatoprostum KDMF to evaluate the safety and efficacy of the drug.
After submitting a bimatoprostum KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their bimatoprostum API can apply through the Korea Drug Master File (KDMF).
click here to find a list of bimatoprostum suppliers with KDMF on PharmaCompass.
A bimatoprostum written confirmation (bimatoprostum WC) is an official document issued by a regulatory agency to a bimatoprostum manufacturer, verifying that the manufacturing facility of a bimatoprostum active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting bimatoprostum APIs or bimatoprostum finished pharmaceutical products to another nation, regulatory agencies frequently require a bimatoprostum WC (written confirmation) as part of the regulatory process.
click here to find a list of bimatoprostum suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing bimatoprostum as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for bimatoprostum API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture bimatoprostum as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain bimatoprostum and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a bimatoprostum NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of bimatoprostum suppliers with NDC on PharmaCompass.
bimatoprostum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of bimatoprostum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right bimatoprostum GMP manufacturer or bimatoprostum GMP API supplier for your needs.
A bimatoprostum CoA (Certificate of Analysis) is a formal document that attests to bimatoprostum's compliance with bimatoprostum specifications and serves as a tool for batch-level quality control.
bimatoprostum CoA mostly includes findings from lab analyses of a specific batch. For each bimatoprostum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
bimatoprostum may be tested according to a variety of international standards, such as European Pharmacopoeia (bimatoprostum EP), bimatoprostum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (bimatoprostum USP).
